secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2026-03-18T23:59:59+00:00
Accession:  0001104659-26-029846
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix reports FY2025 results; EC approves Elfabrio E4W regimen triggering $25M milestone
--------------------------------------------------------------------------------

- EC approved Elfabrio 2mg/kg every-4-weeks dosing for stable adults with Fabry in EU; $25M milestone from Chiesi triggered.
- Total 2026 revenue guided to $78M-$83M including milestone; Elfabrio sales $33-35M, Elelyso $20-23M.
- Phase 2 RELEASE trial for PRX-115 (uncontrolled gout) actively enrolling; top-line data expected H2 2027.
- Company expects cash balance ~$50M by April 2026 with no outstanding debt or warrants.
- No specific FY2025 financial numbers disclosed in the press release; focus on business and regulatory milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/0001104659-26-029846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/plx-20260318x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-029846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer